Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 959

1.

Nigral overexpression of α-synuclein in a rat Parkinson's disease model indicates alterations in the enteric nervous system and the gut microbiome.

O'Donovan SM, Crowley EK, Brown JR, O'Sullivan O, O'Leary OF, Timmons S, Nolan YM, Clarke DJ, Hyland NP, Joyce SA, Sullivan AM, O'Neill C.

Neurogastroenterol Motil. 2019 Oct 2:e13726. doi: 10.1111/nmo.13726. [Epub ahead of print]

PMID:
31576631
2.

Cardiovascular Toxicities Associated With Ibrutinib.

Salem JE, Manouchehri A, Bretagne M, Lebrun-Vignes B, Groarke JD, Johnson DB, Yang T, Reddy NM, Funck-Brentano C, Brown JR, Roden DM, Moslehi JJ.

J Am Coll Cardiol. 2019 Oct 1;74(13):1667-1678. doi: 10.1016/j.jacc.2019.07.056.

PMID:
31558250
3.

Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies.

Guièze R, Liu VM, Rosebrock D, Jourdain AA, Hernández-Sánchez M, Martinez Zurita A, Sun J, Ten Hacken E, Baranowski K, Thompson PA, Heo JM, Cartun Z, Aygün O, Iorgulescu JB, Zhang W, Notarangelo G, Livitz D, Li S, Davids MS, Biran A, Fernandes SM, Brown JR, Lako A, Ciantra ZB, Lawlor MA, Keskin DB, Udeshi ND, Wierda WG, Livak KJ, Letai AG, Neuberg D, Harper JW, Carr SA, Piccioni F, Ott CJ, Leshchiner I, Johannessen CM, Doench J, Mootha VK, Getz G, Wu CJ.

Cancer Cell. 2019 Oct 14;36(4):369-384.e13. doi: 10.1016/j.ccell.2019.08.005. Epub 2019 Sep 19.

PMID:
31543463
4.

Ibrutinib associated invasive fungal diseases in patients with CLL and non-Hodgkin lymphoma: an observational study.

Ruchlemer R, Ben-Ami R, Bar-Meir M, Brown JR, Malphettes M, Mous R, Tonino SH, Soussain C, Barzic N, Messina JA, Jain P, Cohen R, Hill B, Mulligan SP, Nijland M, Herishanu Y, Benjamini O, Tadmor T, Okamoto K, Arthurs B, Gottesman B, Kater AP, Talha M, Eichhorst B, Korem M, Bogot N, De Boer F, Rowe JM, Lachish T.

Mycoses. 2019 Sep 13. doi: 10.1111/myc.13001. [Epub ahead of print]

PMID:
31520441
5.

Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Munir T, Brown JR, O'Brien S, Barrientos JC, Barr PM, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Kipps TJ, Moreno C, Montillo M, Burger JA, Byrd JC, Hillmen P, Dai S, Szoke A, Dean JP, Woyach JA.

Am J Hematol. 2019 Sep 11. doi: 10.1002/ajh.25638. [Epub ahead of print]

PMID:
31512258
6.

Role of Sex in Determining Treatment Type for Patients Undergoing Endovascular Lower Extremity Revascularization.

Ramkumar N, Suckow BD, Brown JR, Sedrakyan A, MacKenzie T, Stone DH, Cronenwett JL, Goodney PP.

J Am Heart Assoc. 2019 Sep 3;8(17):e013088. doi: 10.1161/JAHA.119.013088. Epub 2019 Aug 31.

7.

Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia.

Kipps TJ, Fraser G, Coutre SE, Brown JR, Barrientos JC, Barr PM, Byrd JC, O'Brien SM, Dilhuydy MS, Hillmen P, Jaeger U, Moreno C, Cramer P, Stilgenbauer S, Chanan-Khan AA, Mahler M, Salman M, Eckert K, Solman IG, Balasubramanian S, Cheng M, Londhe A, Ninomoto J, Howes A, James DF, Hallek M.

Clin Lymphoma Myeloma Leuk. 2019 Jul 15. pii: S2152-2650(19)30398-2. doi: 10.1016/j.clml.2019.07.004. [Epub ahead of print]

8.

A comprehensive characterization of chronic norovirus infection in immunodeficient hosts.

Brown LK, Ruis C, Clark I, Roy S, Brown JR, Albuquerque AS, Patel SY, Miller J, Karim MY, Dervisevic S, Moore J, Williams CA, Cudini J, Moreira F, Neild P, Seneviratne SL, Workman S, Toumpanakis C, Atkinson C, Burns SO, Breuer J, Lowe DM.

J Allergy Clin Immunol. 2019 Aug 13. pii: S0091-6749(19)31034-6. doi: 10.1016/j.jaci.2019.07.036. [Epub ahead of print] No abstract available.

9.

Immunofluorescence and image analysis pipeline for Drosophila motor neurons.

Brown JR, Phongthachit C, Sulkowski MJ.

Biol Methods Protoc. 2019;4(1):bpz010. doi: 10.1093/biomethods/bpz010. Epub 2019 Aug 1.

10.

For CLL cells, there's no place like home.

Lampson BL, Brown JR.

Leuk Lymphoma. 2019 Aug 2:1-3. doi: 10.1080/10428194.2019.1646910. [Epub ahead of print] No abstract available.

PMID:
31373247
11.

In Silico Modeling of Biofilm Formation by Nontypeable Haemophilus influenzae In Vivo.

Brown JR, Jurcisek J, Lakhani V, Snedden A, Ray WC, Mokrzan EM, Bakaletz LO, Das J.

mSphere. 2019 Jul 31;4(4). pii: e00254-19. doi: 10.1128/mSphere.00254-19.

12.

Transforming Triplet Vinylnitrene into Triplet Alkylnitrene at Cryogenic Temperatures.

Shields DJ, Sarkar SK, Sriyarathne HDM, Brown JR, Wentrup C, Abe M, Gudmundsdottir AD.

Org Lett. 2019 Sep 20;21(18):7194-7198. doi: 10.1021/acs.orglett.9b01950. Epub 2019 Jul 26.

PMID:
31348664
13.

Galectin-3 as a Predictor of Long-term Survival after Isolated Coronary Artery Bypass Grafting Surgery.

Parker DM, Owens SL, Ramkumar N, Likosky D, DiScipio AW, Malenka DJ, MacKenzie TA, Brown JR.

Ann Thorac Surg. 2019 Jul 20. pii: S0003-4975(19)31038-0. doi: 10.1016/j.athoracsur.2019.05.072. [Epub ahead of print]

PMID:
31336070
14.

Novel Biomarkers Improves Prediction of 365-day Readmission after Pediatric Congenital Heart Surgery.

Parker DM, Everett AD, Stabler ME, Vricella L, Jacobs ML, Jacobs JP, Parikh CR, Pasquali SK, Brown JR.

Ann Thorac Surg. 2019 Jul 16. pii: S0003-4975(19)31035-5. doi: 10.1016/j.athoracsur.2019.05.070. [Epub ahead of print]

PMID:
31323208
15.

The Association Between Cardiac Biomarker NT-proBNP and 30-Day Readmission or Mortality After Pediatric Congenital Heart Surgery.

Parker DM, Everett AD, Stabler ME, Leyenaar J, Vricella L, Jacobs JP, Thiessen-Philbrook H, Parikh C, Greenberg JH, Brown JR.

World J Pediatr Congenit Heart Surg. 2019 Jul;10(4):446-453. doi: 10.1177/2150135119842864.

PMID:
31307305
16.

Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia.

Giacopelli B, Zhao Q, Ruppert AS, Agyeman A, Weigel C, Wu YZ, Gerber MM, Rabe KG, Larson MC, Lu J, Blachly JS, Rogers KA, Wierda WG, Brown JR, Rai KR, Keating M, Rassenti LZ, Kipps TJ, Zenz T, Shanafelt TD, Kay NE, Abruzzo LV, Coombes KR, Woyach JA, Byrd JC, Oakes CC.

Blood. 2019 Aug 22;134(8):688-698. doi: 10.1182/blood.2019000490. Epub 2019 Jul 10.

17.

Biomarkers improve prediction of 30-day unplanned readmission or mortality after paediatric congenital heart surgery.

Brown JR, Stabler ME, Parker DM, Vricella L, Pasquali S, Leyenaar JK, Bohm AR, MacKenzie T, Parikh C, Jacobs ML, Jacobs JP, Everett AD.

Cardiol Young. 2019 Aug;29(8):1051-1056. doi: 10.1017/S1047951119001471. Epub 2019 Jul 10.

PMID:
31290383
18.

Healthcare spending in the State of Louisiana.

Kruger BP, Brown JR.

BMC Health Serv Res. 2019 Jul 9;19(1):471. doi: 10.1186/s12913-019-4275-y.

19.

Cardiac Biomarkers Predict Long-term Survival After Cardiac Surgery.

Ramkumar N, Jacobs JP, Berman RB, Parker DM, MacKenzie TA, Likosky DS, DiScipio A, Malenka DJ, Brown JR.

Ann Thorac Surg. 2019 Jun 27. pii: S0003-4975(19)30893-8. doi: 10.1016/j.athoracsur.2019.04.123. [Epub ahead of print]

PMID:
31255614
20.

Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report.

Kim HT, Ahn KW, Hu ZH, Davids MS, Volpe VO, Antin JH, Sorror ML, Shadman M, Press O, Pidala J, Hogan W, Negrin R, Devine S, Uberti J, Agura E, Nash R, Mehta J, McGuirk J, Forman S, Langston A, Giralt SA, Perales MA, Battiwalla M, Hale GA, Gale RP, Marks DI, Hamadani M, Ganguly S, Bacher U, Lazarus H, Reshef R, Hildebrandt GC, Inamoto Y, Cahn JY, Solh M, Kharfan-Dabaja MA, Ghosh N, Saad A, Aljurf M, Schouten HC, Hill BT, Pawarode A, Kindwall-Keller T, Saba N, Copelan EA, Nathan S, Beitinjaneh A, Savani BN, Cerny J, Grunwald MR, Yared J, Wirk BM, Nishihori T, Chhabra S, Olsson RF, Bashey A, Gergis U, Popat U, Sobecks R, Alyea E, Saber W, Brown JR.

Clin Cancer Res. 2019 Aug 15;25(16):5143-5155. doi: 10.1158/1078-0432.CCR-18-3988. Epub 2019 Jun 28.

PMID:
31253630
21.
22.

A multi-center analysis of readmission after cardiac surgery: Experience of The Northern New England Cardiovascular Disease Study Group.

Trooboff SW, Magnus PC, Ross CS, Chaisson K, Kramer RS, Helm RE, Desaulniers H, De La Rosa RC, Westbrook BM, Duquette D, Brown JR, Olmstead EM, Malenka DJ, Iribarne A.

J Card Surg. 2019 Aug;34(8):655-662. doi: 10.1111/jocs.14086. Epub 2019 Jun 18.

PMID:
31212387
23.

Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.

Davids MS, Brander DM, Kim HT, Tyekucheva S, Bsat J, Savell A, Hellman JM, Bazemore J, Francoeur K, Alencar A, Shune L, Omaira M, Jacobson CA, Armand P, Ng S, Crombie J, LaCasce AS, Arnason J, Hochberg EP, Takvorian RW, Abramson JS, Fisher DC, Brown JR; Blood Cancer Research Partnership of the Leukemia & Lymphoma Society.

Lancet Haematol. 2019 Aug;6(8):e419-e428. doi: 10.1016/S2352-3026(19)30104-8. Epub 2019 Jun 14.

PMID:
31208944
24.

Airway host-microbiome interactions in chronic obstructive pulmonary disease.

Wang Z, Maschera B, Lea S, Kolsum U, Michalovich D, Van Horn S, Traini C, Brown JR, Hessel EM, Singh D.

Respir Res. 2019 Jun 6;20(1):113. doi: 10.1186/s12931-019-1085-z.

25.

Growth dynamics in naturally progressing chronic lymphocytic leukaemia.

Gruber M, Bozic I, Leshchiner I, Livitz D, Stevenson K, Rassenti L, Rosebrock D, Taylor-Weiner A, Olive O, Goyetche R, Fernandes SM, Sun J, Stewart C, Wong A, Cibulskis C, Zhang W, Reiter JG, Gerold JM, Gribben JG, Rai KR, Keating MJ, Brown JR, Neuberg D, Kipps TJ, Nowak MA, Getz G, Wu CJ.

Nature. 2019 Jun;570(7762):474-479. doi: 10.1038/s41586-019-1252-x. Epub 2019 May 29.

PMID:
31142838
26.

Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.

Awan FT, Schuh A, Brown JR, Furman RR, Pagel JM, Hillmen P, Stephens DM, Woyach J, Bibikova E, Charuworn P, Frigault MM, Hamdy A, Izumi R, Linghu B, Patel P, Wang MH, Byrd JC.

Blood Adv. 2019 May 14;3(9):1553-1562. doi: 10.1182/bloodadvances.2018030007.

27.

Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia.

Soumerai JD, Davids MS, Werner L, Fisher DC, Armand P, Amrein PC, Neuberg D, Hochberg EP, Brown JR, Abramson JS.

Leuk Lymphoma. 2019 May 10:1-8. doi: 10.1080/10428194.2019.1608533. [Epub ahead of print]

PMID:
31074316
28.

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia.

Lampson BL, Kim HT, Davids MS, Abramson JS, Freedman AS, Jacobson CA, Armand PA, Joyce RM, Arnason JE, Rassenti LZ, Kipps TJ, Fein J, Fernandes SM, Hanna JR, Fisher DC, Brown JR.

Blood Adv. 2019 Apr 9;3(7):1167-1174. doi: 10.1182/bloodadvances.2018030221.

29.

The opportunity cost of walking away in the spatial iterated prisoner's dilemma.

Premo LS, Brown JR.

Theor Popul Biol. 2019 Jun;127:40-48. doi: 10.1016/j.tpb.2019.03.004. Epub 2019 Apr 1.

PMID:
30946861
30.

Biomarkers associated with 30-day readmission and mortality after pediatric congenital heart surgery.

Parker DM, Everett AD, Stabler ME, Vricella L, Jacobs ML, Jacobs JP, Thiessen-Philbrook H, Parikh CR, Brown JR.

J Card Surg. 2019 May;34(5):329-336. doi: 10.1111/jocs.14038. Epub 2019 Apr 3.

PMID:
30942505
31.

Claims-based surveillance for reintervention after endovascular aneurysm repair among non-Medicare patients.

Columbo JA, Sedrakyan A, Mao J, Hoel AW, Trooboff SW, Kang R, Brown JR, Goodney PP.

J Vasc Surg. 2019 Sep;70(3):741-747. doi: 10.1016/j.jvs.2018.11.031. Epub 2019 Mar 25.

PMID:
30922744
32.

Perceived risk for cancer progression and psychological status in chronic lymphocytic leukemia patients: CALGB 70603 (Alliance).

Deshields TL, Dueck AC, Rogers K, Brown JR, Shanafelt T, Mintzer D, Byrd JC.

Leuk Lymphoma. 2019 Oct;60(10):2580-2583. doi: 10.1080/10428194.2019.1594218. Epub 2019 Mar 27. No abstract available.

PMID:
30916608
33.

Are Urinary Biomarkers Better Than Acute Kidney Injury Duration for Predicting Readmission?

Brown JR, Thiessen-Philbrook H, Goodrich CA, Bohm AR, Alam SS, Coca SG, McArthur E, Garg AX, Parikh CR.

Ann Thorac Surg. 2019 Jun;107(6):1699-1705. doi: 10.1016/j.athoracsur.2019.02.005. Epub 2019 Mar 14.

PMID:
30880140
34.

Prebiotic supplementation in frail older people affects specific gut microbiota taxa but not global diversity.

Tran TTT, Cousin FJ, Lynch DB, Menon R, Brulc J, Brown JR, O'Herlihy E, Butto LF, Power K, Jeffery IB, O'Connor EM, O'Toole PW.

Microbiome. 2019 Mar 13;7(1):39. doi: 10.1186/s40168-019-0654-1.

35.

Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.

Byrd JC, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Thornton P, Moreno C, Montillo M, Pagel JM, Burger JA, Woyach JA, Dai S, Vezan R, James DF, Brown JR.

Blood. 2019 May 9;133(19):2031-2042. doi: 10.1182/blood-2018-08-870238. Epub 2019 Mar 6.

PMID:
30842083
36.

Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis.

O'Brien SM, Byrd JC, Hillmen P, Coutre S, Brown JR, Barr PM, Barrientos JC, Devereux S, Robak T, Reddy NM, Kipps TJ, Tedeschi A, Cymbalista F, Ghia P, Chang S, Ninomoto J, James DF, Burger JA.

Am J Hematol. 2019 May;94(5):554-562. doi: 10.1002/ajh.25436. Epub 2019 Mar 8.

37.

Biomarkers for the prediction of cardiac readmission.

Parker DM, Brown JR.

Biomark Med. 2019 Feb;13(2):55-58. doi: 10.2217/bmm-2018-0381. Epub 2019 Jan 23. No abstract available.

38.

Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL.

Brown JR, O'Brien S, Kingsley CD, Eradat H, Pagel JM, Hirata J, McIver T, Morariu-Zamfir R, Kipps TJ.

Blood. 2019 Feb 28;133(9):990-992. doi: 10.1182/blood-2018-06-857714. Epub 2018 Dec 28. No abstract available.

PMID:
30593446
39.

Inconsistent Inferences.

Ramkumar N, Brown JR.

Circ Cardiovasc Qual Outcomes. 2018 Dec;11(12):e005235. doi: 10.1161/CIRCOUTCOMES.118.005235. No abstract available. Erratum in: Circ Cardiovasc Qual Outcomes. 2019 Feb;12(2):e000053.

PMID:
30562076
40.

Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.

Davids MS, Kim HT, Nicotra A, Savell A, Francoeur K, Hellman JM, Bazemore J, Miskin HP, Sportelli P, Stampleman L, Maegawa R, Rueter J, Boruchov AM, Arnason JE, Jacobson CA, Jacobsen ED, Fisher DC, Brown JR; Blood Cancer Research Partnership of the Leukemia and Lymphoma Society.

Lancet Haematol. 2019 Jan;6(1):e38-e47. doi: 10.1016/S2352-3026(18)30196-0. Epub 2018 Dec 14.

PMID:
30558987
41.

DUO delivers for duvelisib.

Brown JR.

Blood. 2018 Dec 6;132(23):2422-2424. doi: 10.1182/blood-2018-10-879650. No abstract available.

42.

Ibrutinib: searching for a partner drug.

Kater AP, Brown JR.

Lancet Oncol. 2019 Jan;20(1):3-5. doi: 10.1016/S1470-2045(18)30861-1. Epub 2018 Dec 3. No abstract available.

PMID:
30522966
43.

MYD88 L265P mutations identify a prognostic gene expression signature and a pathway for targeted inhibition in CLL.

Improgo MR, Tesar B, Klitgaard JL, Magori-Cohen R, Yu L, Kasar S, Chaudhary D, Miao W, Fernandes SM, Hoang K, Westlin WF, Kim HT, Brown JR.

Br J Haematol. 2019 Mar;184(6):925-936. doi: 10.1111/bjh.15714. Epub 2018 Dec 9.

PMID:
30537114
44.

Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis.

Brown JR, Moslehi J, Ewer MS, O'Brien SM, Ghia P, Cymbalista F, Shanafelt TD, Fraser G, Rule S, Coutre SE, Dilhuydy MS, Cramer P, Jaeger U, Dreyling M, Byrd JC, Treon S, Liu EY, Chang S, Bista A, Vempati R, Boornazian L, Valentino R, Reddy V, Mahler M, Yang H, Graef T, Burger JA.

Br J Haematol. 2019 Feb;184(4):558-569. doi: 10.1111/bjh.15690. Epub 2018 Dec 2.

45.

Relapsed CLL: sequencing, combinations, and novel agents.

Brown JR.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):248-255. doi: 10.1182/asheducation-2018.1.248. Review.

PMID:
30504318
46.

Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia.

Ott CJ, Federation AJ, Schwartz LS, Kasar S, Klitgaard JL, Lenci R, Li Q, Lawlor M, Fernandes SM, Souza A, Polaski D, Gadi D, Freedman ML, Brown JR, Bradner JE.

Cancer Cell. 2018 Dec 10;34(6):982-995.e7. doi: 10.1016/j.ccell.2018.11.001. Epub 2018 Nov 29.

PMID:
30503705
47.

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.

Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Coutre S, Hurria A, Brown JR, Lozanski G, Blachly JS, Ozer HG, Major-Elechi B, Fruth B, Nattam S, Larson RA, Erba H, Litzow M, Owen C, Kuzma C, Abramson JS, Little RF, Smith SE, Stone RM, Mandrekar SJ, Byrd JC.

N Engl J Med. 2018 Dec 27;379(26):2517-2528. doi: 10.1056/NEJMoa1812836. Epub 2018 Dec 1.

48.

sST2 as a novel biomarker for the prediction of in-hospital mortality after coronary artery bypass grafting.

Stabler ME, Rezaee ME, Parker DM, MacKenzie TA, Bohm AR, DiScipio AW, Malenka DJ, Brown JR.

Biomarkers. 2019 May;24(3):268-276. doi: 10.1080/1354750X.2018.1556338. Epub 2019 Jan 11.

PMID:
30512977
49.

PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression.

Dong S, Harrington BK, Hu EY, Greene JT, Lehman AM, Tran M, Wasmuth RL, Long M, Muthusamy N, Brown JR, Johnson AJ, Byrd JC.

J Clin Invest. 2019 Jan 2;129(1):122-136. doi: 10.1172/JCI99386. Epub 2018 Nov 19.

50.

Correction to: Chronic Aichi Virus Infection in a Patient with X-Linked Agammaglobulinemia.

Bucciol G, Moens L, Payne K, Wollants E, Mekahli D, Levtchenko E, Vermeulen F, Tousseyn T, Gray P, Ma CS, Tangye SG, Van Ranst M, Brown JR, Breuer J, Meyts I.

J Clin Immunol. 2018 Nov;38(8):938-939. doi: 10.1007/s10875-018-0570-3.

PMID:
30430354

Supplemental Content

Loading ...
Support Center